九芝堂品牌怎么样 申请店铺

我要投票 九芝堂在阿胶行业中的票数:805 更新时间:2026-01-05
九芝堂是哪个国家的品牌?「九芝堂」是 九芝堂股份有限公司 旗下著名品牌。该品牌发源于湖南省长沙市,由创始人李振国在1999-05-12期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力九芝堂品牌出海!将品牌入驻外推网,定制九芝堂品牌推广信息,可以显著提高九芝堂产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

九芝堂怎么样

九芝堂股份有限公司是国家重点中药企业,国内A股上市公司,湖南省重点高新技术企业,湖南省百强企业,湖南省质量管理奖企业,长沙市工业十大标志性工程龙头企业,国家博士后科研工作站企业。

九芝堂前身“劳九芝堂药铺”创建于1650年。2004年2月,“九芝堂”商标被国家工商行政管理总局商标局认定为中国驰名商标;2006年9月,“九芝堂”被国家商务部认定为“中华老字号”;2008年6月,九芝堂传统中药文化被列入国家级非物质文化遗产保护目录。

截至2009年底,公司已发展成为拥有总资产15.48亿元,净资产12.57亿元,下辖7家直接控股子公司、3家间接控股子公司,1家分公司,年销售过12亿元,利税过3亿元的工商一体化的现代大型医药企业。

公司主要从事补血系列、补益系列、肝炎系列等中药以及调节人体免疫力的生物制剂的生产与销售,正在形成销售过亿产品、过千万产品、迅速成长产品构成的一个产品阶梯,为可持续发展奠定了产品基础。主导产品驴胶补血颗粒年销售收入超过3亿元,位于全国天然补血类产品销售前三名;以六味地黄丸为代表的浓缩丸系列销售收入突破2亿元,位于全国同种产品销售前三名;斯奇康注射液销售收入1亿元。公司的中成药片剂、浓缩丸系列产品等出口欧美、日本、东南亚等地区,其中十多种浓缩丸、片剂出口日本已将近20年。九芝堂的产品不仅是济世良药,也是一种文化载体,九芝堂人不仅是客商,也成为了文化使节。

公司综合经济实力在湖南省医药行业中排名第一,已成为湖南省“十一五”重点发展的现代中药及生物医药优势产业集群的核心企业。2006年8月,在“首届中华老字号品牌价值百强榜”上,九芝堂以13.55亿的品牌价值排在第13位。2007年4月,九芝堂被《医药经济报》评为“中国制药工业企业百强”。2008年12月,公司通过湖南省科学技术厅的再认定,蝉联“高新技术企业”称号。

“九州共济、芝兰同芳”,面对激烈的市场竞争,九芝堂谋求和谐合作,共同发展。九芝堂将秉承三百多年优良的制药传统,把自主创新作为推动公司可持续发展的主导力量,立足民生、民情,发展现代中药产业,适度介入生物制品,开发消费者最为需要的产品,改善人类健康生活,致力于成为百亿市值企业。

Jiuzhitang Co., Ltd. is a national key traditional Chinese medicine enterprise, A-share listed company in China, key high-tech enterprise in Hunan Province, top 100 enterprise in Hunan Province, quality management award enterprise in Hunan Province, ten leading industrial engineering enterprises in Changsha City, and National Postdoctoral Research Station enterprise. The predecessor of Jiuzhitang, laojiuzhitang pharmacy, was founded in 1650. In February 2004, the trademark of "Jiuzhitang" was recognized as a well-known trademark by the Trademark Office of the State Administration for Industry and commerce; in September 2006, the trademark of "Jiuzhitang" was recognized as a "Chinese time-honored brand" by the Ministry of Commerce; in June 2008, the traditional Chinese medicine culture of Jiuzhitang was listed in the national intangible cultural heritage protection catalogue. By the end of 2009, the company has developed into a modern large-scale pharmaceutical enterprise with total assets of 1.548 billion yuan and net assets of 1.257 billion yuan. It has seven directly controlled subsidiaries, three indirectly controlled subsidiaries and one branch, with annual sales of 1.2 billion yuan and profits and taxes of 300 million yuan. The company is mainly engaged in the production and sales of traditional Chinese medicine such as blood tonic series, tonic series, hepatitis series and biological preparations regulating human immunity. It is forming a product ladder consisting of over 100 million products, over 10 million products and rapidly growing products, laying a product foundation for sustainable development. The annual sales revenue of lvjiao Buxue granules, the leading product, is more than 300 million yuan, which is located in the top three sales of natural Buxue products in China; the sales revenue of concentrated pill series represented by Liuwei Dihuang pill is more than 200 million yuan, which is located in the top three sales of the same kind of products in China; the sales revenue of Siqikang injection is 100 million yuan. The company's Chinese patent medicine tablets and concentrated pill series products are exported to Europe, America, Japan, Southeast Asia and other regions, among which more than ten kinds of concentrated pills and tablets have been exported to Japan for nearly 20 years. Jiuzhitang's products are not only good medicine for the world, but also a cultural carrier. Jiuzhitang people are not only merchants, but also cultural envoys. The company's comprehensive economic strength ranks first in the pharmaceutical industry of Hunan Province, and it has become the core enterprise of modern Chinese medicine and biomedical industry cluster which is the key development of "11th Five Year Plan" in Hunan Province. In August 2006, Jiuzhitang ranked 13th in the "top 100 list of brand value of the first time-honored Chinese brands". In April 2007, Jiuzhitang was named "top 100 pharmaceutical enterprises in China" by pharmaceutical economic news. In December 2008, the company passed the reappraisal of science and Technology Department of Hunan Province and won the title of "high and new technology enterprise". In the face of fierce market competition, Jiuzhitang seeks for harmonious cooperation and common development. Jiuzhitang will adhere to the excellent pharmaceutical tradition of more than three hundred years, take independent innovation as the leading force to promote the sustainable development of the company, based on the people's livelihood and the people's conditions, develop the modern Chinese medicine industry, moderately intervene in biological products, develop the products most needed by consumers, improve the healthy life of human beings, and strive to become a 10 billion market value enterprise.

本文链接: https://brand.waitui.com/7e3ceb284.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

旭升集团:收到北美新能源汽车厂商定点通知,预计生命周期总销售金额约78亿元

36氪获悉,旭升集团公告,公司收到北美新能源汽车厂商的定点通知,将为其供应动力总成、车身件、副车架、电池盒等零部件产品。根据客户规划,此次定点项目生命周期约为8年,生命周期总销售金额约人民币78亿元,预计在2026年底开始量产。

2分钟前

惠而浦:预计2025年归母净利润5.05亿元左右,同比增加150%左右

36氪获悉,惠而浦公告, 经公司财务部门初步测算,预计2025年年度实现归属于母公司所有者的净利润5.05亿元左右,与上年同期(法定披露数据)相比,将增加约3.03亿元左右,同比增加150%左右。

2分钟前

金瑞矿业:全资子公司停产检修,预计不超过60天

36氪获悉,金瑞矿业公告,公司全资子公司重庆庆龙精细锶盐化工有限公司、重庆庆龙新材料科技有限公司决定自2026年1月5日开始进行生产系统及设备全面停产检修,预计所需时间不超过60天。此次停产检修为年度例行计划,对公司全年生产经营计划的完成及经营状况无重大影响。

2分钟前

康迪科技联合浙江大学共建智能机器人联合研发中心

36氪获悉,2026年1月5日,康迪科技与浙江大学联合宣布,浙江大学-康迪智能机器人联合研发中心正式成立。据了解,该中心将聚焦北美市场对智能化安防巡检的需求,围绕四足机器人的智能感知、空间计算等核心技术开展联合攻关。

2分钟前

3连板南兴股份:预计2025年净利润9000万元-1.2亿元,同比扭亏为盈

36氪获悉,南兴股份公告,预计归属于上市公司股东的净利润为9000万元–1.2亿元,上年同期亏损1.75亿元。报告期内,公司净利润大幅增长的主要原因是2024年度计提商誉减值3.64亿元,导致2024年度净利润大幅减少。而本年度IDC业务的业绩有所增长,根据初步商誉减值测试的结果,商誉减值对本报告期利润影响较少,因此2025年度净利润比去年同期会有大幅度增长。

2分钟前

本页详细列出关于九芝堂的品牌信息,含品牌所属公司介绍,九芝堂所处行业的品牌地位及优势。
咨询